Endoscopic Retrograde Cholangiopancreatography Market Research Report Information By Procedure (Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation, Pancreatic Duct Stenting and Others), By End User (Hospitals & Clinics and Ambulatory Surgical Centers), By Application (Bile Duct, Pancreas and Others), By Product (Endoscopes (Endotherapy Devices, Catheters, Stents, Balloons, Guiding Wires, Others), Imaging Devices and Energy Devices), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 20

Global Endoscopic Retrograde Cholangiopancreatography Market Overview

Endoscopic Retrograde Cholangiopancreatography Market Size was valued at USD 1.9 Billion in 2022. The endoscopic retrograde cholangiopancreatography market industry is projected to grow from USD 2.08 Billion in 2023 to USD 4.407 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.80% during the forecast period (2023 - 2032). One of the primary market driver favorably affecting the market is the expanding  population as well as the rising prevalence of various chronic gastrointestinal (GI) and persistent biliary medical disorders, such as Barrett's disease, biliary, Crohn's, inflammatory bowel, liver, and peptic ulcer disease, as well as gastroesophageal reflux disorder (GERD).

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Endoscopic Retrograde Cholangiopancreatography Market Trends

• Rising application of ERCP is driving the market growth

ERCP, also known as endoscopic retrograde cholangiopancreatography, is a method for identifying and treating problems with the pancreas, liver, gallbladder, and bile ducts. Endoscopic retrograde cholangiopancreatography (ERCP) is a procedure for diagnosing and treating pancreatobiliary diseases that combines luminal endoscopy with imaging based on fluoroscopy. It combines the use of an endoscope, a protracted, bendable, and illuminated tube, and X-ray technology. Undiagnosed stomach pain or jaundice, which causes the skin and eyes to turn yellow, may be the result of something that can be found out using ERCP. If there is pancreatitis or liver, pancreas, or bile duct cancer, it can be used to learn more about such conditions. Endoscopic retrograde cholangiopancreatography (ERCP) can also detect diseases including bile duct obstructions or stones, as well as liquid discharge from the bile or pancreatic ducts. Other disorders that might be found with an ERCP include tumours, obstructions or limitations of the pancreatic ducts, and pollution in the bile ducts. Consequently, the market CAGR for endoscopic retrograde cholangiopancreatography is expanding.

Various organs of the digestive system, including the liver, pancreas, and gallbladder, are affected by gastrointestinal (Gl) illnesses. Gl diseases are a major contributor to worldwide morbidity and mortality and have a profound impact on millions of people. For instance, the 2019 International Foundation for Gastrointestinal Disorders Report states that GED affects roughly one-third of the population and is a major cause of bleeding issues, which is what is driving the expansion of the  market. The National Institutes of Health invested up to $1.6 billion in Gl research in 2017; Gl diseases impact 60–70 million Americans annually. Primary biliary cholangitis (PBC) incidence, on the other hand, ranges from 5.8 to 15 cases per million people. The governments' attention has been called by a significant increase in the fatality rate, and as a result, the demand for treatment is expected to rise over the predicted period.

The usage of endoscopic equipment in the field of ERCP has increased in tandem with a quicker rate of population ageing worldwide. Visual impairment is occurring more frequently now than it ever has before due to population ageing. Comorbidities such as adenomas, hemangiomas, focal nodular hyperplasia (FNH), and pancreatic cancer have so been noted. The fourth most prevalent type of cancer in the world, pancreatic cancer, is what kills people the most. In the United States, 68.5% of pancreatic cancer diagnoses are made in people over 65, according to the National Cancer Database. The number of old people with gastrointestinal and chronic biliary problems, as well as benign liver and pancreatic tumors, will rise as the elderly population rises. Thus, driving the endoscopic retrograde cholangiopancreatography market revenue.

Endoscopic Retrograde Cholangiopancreatography Market Segment Insights

Endoscopic Retrograde Cholangiopancreatography Procedure Insights

The  endoscopic retrograde cholangiopancreatography market segmentation, based on procedure includes Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation, Pancreatic Duct Stenting and Others. The biliary sphincterotomy segment dominated the market. The biliary sphincter and the intraduodenal portion of the common bile duct are both severed using a high-frequency current following selective cannulation using a sphincterotome, a specialised knife inserted into the papilla. Biliary endoscopic sphincterotomy (EST), also known as biliary sphincterotomy, is the name of this procedure.

Endoscopic Retrograde Cholangiopancreatography End User Insights

The  endoscopic retrograde cholangiopancreatography market segmentation, based on end user, includes Hospitals & Clinics and Ambulatory Surgical Centers. Hospitals & clinics category generated the most income. This increase can be attributed to the accelerated expansion of the healthcare infrastructure in North America and Europe, which has aided in the financial growth of hospitals. This market is expanding as a result of the increasing patient demand for hospital-based care utilising sphincterotomes and for clinics to provide better preventive care and more advanced treatment choices.

Figure 1  Endoscopic Retrograde Cholangiopancreatography Market, by End User, 2022 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Endoscopic Retrograde Cholangiopancreatography Application Insights

The  endoscopic retrograde cholangiopancreatography market segmentation, based on product includes Bile Duct, Pancreas and Others. The bile duct segment dominated the market. Bile duct, stone, and structure-related disorders are diagnosed and treated with endoscopic retrograde cholangiopancreatography. Gallstones or sludge are the culprits behind the bile duct obstruction. Gallbladder stones are also more common in emerging countries and are influenced by changes in lifestyle.

Endoscopic Retrograde Cholangiopancreatography Product Insights

The  endoscopic retrograde cholangiopancreatography market segmentation, based on product includes Endoscopes (Endotherapy Devices, Catheters, Stents, Balloons, Guiding Wires, Others), Imaging Devices and Energy Devices. The endoscopes segment dominated the market. In the upcoming years, it is anticipated that the market for endoscopic retrograde cholangiopancreatography devices for endoscopes will grow significantly as a result of a growth in gastrointestinal and chronic biliary problems.

Endoscopic Retrograde Cholangiopancreatography Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American endoscopic retrograde cholangiopancreatography market area will dominate this market. This region is expanding as a result of intensive diagnostic imaging research and the rapid introduction of technologically advanced ERCP tools like sphincterotomes. The expansion of government healthcare funding and the presence of important companies like Hobbs Medical Inc. in the area are both contributing to the growth.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2  ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe endoscopic retrograde cholangiopancreatography market accounts for the second-largest market share due to the enormous negative impact biliary and pancreatic problems have on people's general health. These illnesses include Crohn's disease, inflammatory bowel disease, liver disease, pancreatitis, and gastroesophageal reflux disease (GERD). When the diseases have not been discovered in their earliest stages, surgical intervention is necessary to treat these problems in severe cases.  Further, the German endoscopic retrograde cholangiopancreatography market held the largest market share, and the UK endoscopic retrograde cholangiopancreatography market was the fastest growing market in the European region.

The Asia-Pacific Endoscopic retrograde cholangiopancreatography Market is expected to grow at the fastest CAGR from 2023 to 2032. The expansion of the healthcare industry is responsible for this growth. The growth of the Endoscopic Retrograde Cholangiopancreatography Market in the Asia-Pacific region is also being fueled by the rising awareness of the use of spincterotomes in the treatment of pancreatic and liver disorders. Moreover, China’s endoscopic retrograde cholangiopancreatography market held the largest market share, and the Indian endoscopic retrograde cholangiopancreatography market was the fastest growing market in the Asia-Pacific region.

Endoscopic Retrograde Cholangiopancreatography Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the endoscopic retrograde cholangiopancreatography market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, endoscopic retrograde cholangiopancreatography industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  endoscopic retrograde cholangiopancreatography industry to benefit clients and increase the market sector. In recent years, the endoscopic retrograde cholangiopancreatography industry has offered some of the most significant advantages to market. Major players in the endoscopic retrograde cholangiopancreatography market attempting to increase market demand by investing in research and development operations include Olympus Corporation (Japan), Fujifilm Holdings, Corporation (Japan), STERIS PLC (UK), Cook Medical (US), Boston Scientific Corporation (US), CONMED Corporation (US), HOYA Group (Japan), Q3 Medical Devices Limited (Ireland), Ambu Inc. (Denmark), Medtronic Plc (Ireland), and Others.

A corporation called Olympus Corp (Olympus) manufactures precise equipment and tools for optical and digital technologies. The company designs, manufactures, and distributes equipment and devices for the healthcare, information, medical, imaging, and other industrial industries. It offers medical systems like endotherapy devices, endoscopes, and endoscopy supplies to aid medical professionals in treating patients, as well as scientific solutions like laser scanning microscopes, remote visual inspection products, industrial and biological microscope systems, and non-destructive testing systems. In February 2020, the FDA has given Olympus' TJF-Q190V duodenoscope approval. The product provides an antiseptic and disposable distal endcap made to reduce contamination and improve machine reprocessing.

ConMed Corp (ConMed) is a producer and distributor of surgical tools and instruments for minimally invasive treatments and monitoring. Arthroscopes, bronchoscopy tools, reconstructive systems, endoscopic ligator kits, trocars, balloons for stone removal, graspers, and scissors, suction irrigation tools, thermal tissue fusion systems, electrosurgical generators, pencil sheaths, smoke evacuation pencils, saws, and blades, endo mechanical instrumentation, and surgical visualization tools are some of the company's main products.

Key Companies in the endoscopic retrograde cholangiopancreatography market include

• Olympus Corporation (Japan)


• Fujifilm Holdings, Corporation (Japan)


• STERIS PLC (UK)


• Cook Medical (US)


• Boston Scientific Corporation (US)


• CONMED Corporation (US)


• HOYA Group (Japan)


• Q3 Medical Devices Limited (Ireland)


• Ambu Inc. (Denmark)


• Medtronic Plc (Ireland)


• Others

Endoscopic Retrograde Cholangiopancreatography Industry Developments

February 2023 The introduction of the High-Throughput Single-Cell Multiomics Platform by BD was made to increase the scope of scientific discovery.

February 2023 The FDA has given the LithoVueTM Elite Single-Use Digital Flexible Ureteroscope System by Boston Scientific its approval.

February 2022 Ambu A/S announced that the Ambu aBox and Ambu aScope Gastro products have received 510(k) regulatory clearance for the American market. The aScope Gastro is a first-of-its-kind sterile, single-use gastroscope that has cutting-edge, enhanced imaging and design characteristics as well as a next-generation display and CPU.

January 2022 Cook Medical (US) introduced the Instinct Plus endoscopic clipping tool, which is compatible with a duodenoscope and has uses for preventive clipping, anchoring treatments, and defect closure in the GI tract.

Endoscopic Retrograde Cholangiopancreatography Market Segmentation

Endoscopic Retrograde Cholangiopancreatography Procedure Outlook (USD Billion, 2018-2032)

• Biliary Sphincterotomy


• Biliary Stenting


• Biliary Dilatation


• Pancreatic Duct Stenting


• Others

Endoscopic Retrograde Cholangiopancreatography End User Outlook (USD Billion, 2018-2032)

• Hospitals & Clinics


• Ambulatory Surgical Centers

Endoscopic Retrograde Cholangiopancreatography Application Outlook (USD Billion, 2018-2032)

• Bile Duct


• Pancreas


• Others

Endoscopic Retrograde Cholangiopancreatography Product Outlook (USD Billion, 2018-2032)

• Endoscopes




• Endotherapy Devices


• Catheters


• Stents


• Balloons


• Guiding Wires


• Others




• IMAGING DEVICES


• Energy Devices

Endoscopic Retrograde Cholangiopancreatography Regional Outlook (USD Billion, 2018-2032)

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America
  
  
  
  

Report Scope:

Endoscopic Retrograde Cholangiopancreatography Report Scope

Report Attribute/Metric	Details
Market Size 2022	USD 1.9 Billion
Market Size 2023	USD 2.08 Billion
Market Size 2032	USD 4.407 Billion
Compound Annual Growth Rate (CAGR)	9.80% (2023-2032)
Base Year	2022
Market Forecast Period	2023-2032
Historical Data	2018- 2022
Market Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered	Procedure, End User, Application, Product, and Region
Geographies Covered	North America, Europe, Asia Pacific, and the Rest of the World
Countries Covered	The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled	Olympus Corporation (Japan), Fujifilm Holdings, Corporation (Japan), STERIS PLC (UK), Cook Medical (US), Boston Scientific Corporation (US), CONMED Corporation (US), HOYA Group (Japan), Q3 Medical Devices Limited (Ireland), Ambu Inc. (Denmark), Medtronic Plc (Ireland), and Others
Key Market Opportunities	Rising demand for minimally invasive surgeries
Key Market Dynamics	Increasing prevalence of gastrointestinal diseases (GIT) associated with the pancreas and bile ducts  Technological advancements

Frequently Asked Questions (FAQ) :